| Market Capitalization (Millions $) |
786 |
| Shares
Outstanding (Millions) |
53 |
| Employees |
80 |
| Revenues (TTM) (Millions $) |
20 |
| Net Income (TTM) (Millions $) |
-218 |
| Cash Flow (TTM) (Millions $) |
-28 |
| Capital Exp. (TTM) (Millions $) |
1 |
Uniqure N V
Uniqure N.V. is a gene therapy company headquartered in the Netherlands, with a focus on developing treatments for genetic and rare diseases. The company was founded in 1999 and has since become a leading player in the gene therapy industry.
The company's pipeline includes several candidates in clinical and pre-clinical development. One of its most promising programs is AMT-061, a gene therapy for patients with hemophilia B. Uniqure N.V. also has a collaboration with CSL Behring to develop gene therapies for hemophilia A and B.
Uniqure N.V. has established partnerships with major pharmaceutical companies, including Pfizer, Bristol-Myers Squibb, and AbbVie. The company has also received funding from the European Union to support its research and development efforts.
Overall, Uniqure N.V. is working to advance gene therapy as a new approach to treating genetic and rare diseases, and its innovative therapies are expected to have a significant impact on patients' lives.
Company Address: Paasheuvelweg 25a Amsterdam 1105
Company Phone Number: 20-240-6000 Stock Exchange / Ticker: NASDAQ QURE
|
1.31% 
100 %